FDC Limited
Valuation (94/100) does the heavy lifting; quality (70/100) is the drag.
Buy zoneFDC Limited earns a Strong Buy from StocksWizard, with a blended score of 82/100. On 23.7x trailing earnings it sits cheaper than the Healthcare median of about 37.6x. The price is about 15% below its 52-week high of ₹480.72 and 28% above the low of ₹321.1. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 5/9. It clears 10 of 13 investability checks, with durability 70, valuation 88 and momentum 75 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹516.67.
1-year price
EOD · 2026-07-3152-week range
-14.75% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Strong Buy82Piotroski F-score 5/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 11.8%
- Pass: Low debt (D/E < 0.5): 0.01x
- Fail: Positive free cash flow
- Pass: Revenue growth > 10%: 19%
- Pass: Earnings growing: 167%
- Pass: Net margin ≥ 10%: 13.0%
- Pass: Current ratio > 1.5: 3.11
- Pass: Below our fair value
- Pass: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 11.02
- Fail: Piotroski ≥ 7: 5/9
Quarterly results
Annual financials
Shareholding
- Promoter70.0%
- Institutions7.3%
- Public & other22.7%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Financially solid — Altman Z 11.02.
Opportunities
- Earnings growing (167% YoY).
- Revenue growing (19% YoY).
- Trading in our value buy zone versus sector peers.
- Trades ~58% below our estimated fair value.
About FDC Limited
FDC Limited manufactures and trades pharmaceutical products across India, the United States, and international markets. The company produces formulations in multiple therapeutic areas including anti-infectives, gastrointestinal, ophthalmology, vitamins, minerals, dietary supplements, cardiovascular, anti-diabetic, respiratory, gynecology, dermatology, and analgesics in tablet, capsule, oral liquid, and other forms.
FDC Limited — frequently asked questions
Is FDC Limited a buy, hold or sell?
StocksWizard currently rates FDC Limited (FDC) a Strong Buy, based on a blended score of 82/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is FDC Limited's fair value?
Our blended DCF and relative-valuation model estimates FDC Limited's fair value at about ₹645.84, versus a current price of ₹409.8 — roughly 58% upside. On that basis the stock looks undervalued by 58%.
Is FDC Limited financially healthy?
FDC Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 5/9.
How has FDC Limited's share price performed?
FDC Limited is up 11% over three months, and last traded at ₹409.8. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.